Amphastar Pharmaceuticals (AMPH) Long-Term Deferred Tax (2013 - 2026)

Amphastar Pharmaceuticals' Long-Term Deferred Tax history runs 14 years deep, the most recent figure standing at $42.5 million for Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax fell 40.3% year-over-year to $42.5 million in Q1 2026; TTM through Mar 2026 was $42.5 million, a 40.3% decrease from a year earlier, with the FY2025 full-year figure at $42.5 million, down 40.3% from the prior year.
• Long-Term Deferred Tax steadied at $42.5 million in Q1 2026 per AMPH's latest filing, from $42.5 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $71.1 million in Q4 2024 and bottomed at $22.4 million in Q1 2022.
• The 5-year median for Long-Term Deferred Tax is $42.5 million (2025), against an average of $47.6 million.
• Across the five-year window, Long-Term Deferred Tax soared 82.45% in 2023 and plunged 40.3% in 2025, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $38.5 million in 2022, then surged by 38.22% to $53.3 million in 2023, then jumped by 33.56% to $71.1 million in 2024, then slumped by 40.3% to $42.5 million in 2025, then changed by 0.0% to $42.5 million in 2026.
• Per Business Quant, the three latest AMPH Long-Term Deferred Tax figures stand at $42.5 million (Q1 2026), $42.5 million (Q4 2025), and $71.1 million (Q3 2025).